Idiopathic Pulmonary Fibrosis Management: Caring is Sparing

Overview

Journal J Thorac Dis

Publisher AME Publishing Company

Specialty Pulmonary Medicine

Date 2020 Nov 19

PMID 33209360

Authors

Stefano Nava

Irene Prediletto

Affiliations

Soon will be listed here.

References

Kassirer J . Doctor discontent. N Engl J Med. 1998; 339(21):1543-5. DOI: 10.1056/NEJM199811193392109. View

Zou R, Kass D, Gibson K, Lindell K . The Role of Palliative Care in Reducing Symptoms and Improving Quality of Life for Patients with Idiopathic Pulmonary Fibrosis: A Review. Pulm Ther. 2020; 6(1):35-46. PMC: 7229085. DOI: 10.1007/s41030-019-00108-2. View

Flaherty K, Fell C, Huggins J, Nunes H, Sussman R, Valenzuela C . Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis. Eur Respir J. 2018; 52(2). PMC: 6092682. DOI: 10.1183/13993003.00230-2018. View

Meltzer E, Noble P . Idiopathic pulmonary fibrosis. Orphanet J Rare Dis. 2008; 3:8. PMC: 2330030. DOI: 10.1186/1750-1172-3-8. View

Matsuda T, Taniguchi H, Ando M, Kondoh Y, Kimura T, Kataoka K . Depression Is Significantly Associated with the Health Status in Patients with Idiopathic Pulmonary Fibrosis. Intern Med. 2017; 56(13):1637-1644. PMC: 5519463. DOI: 10.2169/internalmedicine.56.7019. View

Palmieri J, Stern T . Lies in the doctor-patient relationship. Prim Care Companion J Clin Psychiatry. 2009; 11(4):163-8. PMC: 2736034. DOI: 10.4088/PCC.09r00780. View

Burdi M, Baker L . Physicians' perceptions of autonomy and satisfaction in California. Health Aff (Millwood). 1999; 18(4):134-45. DOI: 10.1377/hlthaff.18.4.134. View

Maher T, Swigris J, Kreuter M, Wijsenbeek M, Cassidy N, Ireland L . Identifying Barriers to Idiopathic Pulmonary Fibrosis Treatment: A Survey of Patient and Physician Views. Respiration. 2018; 96(6):514-524. DOI: 10.1159/000490667. View

Curtis J . Palliative and end-of-life care for patients with severe COPD. Eur Respir J. 2007; 32(3):796-803. DOI: 10.1183/09031936.00126107. View

10.

Gross D, Zyzanski S, Borawski E, Cebul R, Stange K . Patient satisfaction with time spent with their physician. J Fam Pract. 1998; 47(2):133-7. View

11.

Hambly N, Goodwin S, Aziz-Ur-Rehman A, Makhdami N, Ainslie-Garcia M, Grima D . A cross-sectional evaluation of the idiopathic pulmonary fibrosis patient satisfaction and quality of life with a care coordinator. J Thorac Dis. 2020; 11(12):5547-5556. PMC: 6988068. DOI: 10.21037/jtd.2019.11.41. View

12.

Raghu G, Remy-Jardin M, Myers J, Richeldi L, Ryerson C, Lederer D . Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018; 198(5):e44-e68. DOI: 10.1164/rccm.201807-1255ST. View

13.

Maher T, Strek M . Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat. Respir Res. 2019; 20(1):205. PMC: 6731623. DOI: 10.1186/s12931-019-1161-4. View

14.

Lin C, Albertson G, Schilling L, Cyran E, Anderson S, Ware L . Is patients' perception of time spent with the physician a determinant of ambulatory patient satisfaction?. Arch Intern Med. 2001; 161(11):1437-42. DOI: 10.1001/archinte.161.11.1437. View

15.

Mechanic D . Physician discontent: challenges and opportunities. JAMA. 2003; 290(7):941-6. DOI: 10.1001/jama.290.7.941. View

16.

Zurkova M, Kriegova E, Kolek V, Lostakova V, Sterclova M, Bartos V . Effect of pirfenidone on lung function decline and survival: 5-yr experience from a real-life IPF cohort from the Czech EMPIRE registry. Respir Res. 2019; 20(1):16. PMC: 6341650. DOI: 10.1186/s12931-019-0977-2. View

17.

Rodriguez-Portal J . Efficacy and Safety of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis: An Update. Drugs R D. 2017; 18(1):19-25. PMC: 5833905. DOI: 10.1007/s40268-017-0221-9. View

18.

Ryerson C, Arean P, Berkeley J, Carrieri-Kohlman V, Pantilat S, Landefeld C . Depression is a common and chronic comorbidity in patients with interstitial lung disease. Respirology. 2012; 17(3):525-32. DOI: 10.1111/j.1440-1843.2011.02122.x. View